CardiomyopathyOccurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States
Section snippets
Methods
We queried a large proprietary integrated claims database (Symphony Health Solutions [SHS], Phoenix, Arizona), which includes medical condition diagnostic codes (International Classification of Diseases, Ninth Revision [ICD-9]) for over 160 million individual patients (>1/2 census population of 316,159,818 in 20134) in the United States. These claims are captured in each of the US states and include all insurance types, including Medicare and Medicaid. The database is composed of electronically
Results
Over the study period, 169,089,614 unique patients were identified, of which 59,009 had ≥1 HC diagnostic claim (Figure 1). The final occurrence of diagnosed HC in the United States for 2013 was estimated to be 1:3,195. This prevalence estimate yielded a total of 98,958 patients with HC, approximately half of whom are presumed to be symptomatic based on previous large HC cohort studies.3, 6 The average age of HC diagnosis was in the fifth decade of life, with 43% of the HC cohort comprised
Discussion
Leveraging a claims-based analytic technique, the number of clinically diagnosed patients with HC in the US is about 100,000 patients. This figure represents the first reasonable estimate on which nationwide resource allocation and health care burden related to HC can be evaluated. Of note, although considerable in absolute terms, the frequency with which patients are diagnosed with HC and seek medical care contrasts sharply with the much higher estimated occurrence of unrecognized disease
Disclosures
Dr. Maron had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The study was funded by Gilead Sciences, Inc. The sponsor was involved in design and conduct of the study; interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. Drs. Maron, Olivotto, and Lucove report receiving consulting fees from Gilead Sciences, Inc. Drs. Hellawell
References (8)
- et al.
Determinants for clinical diagnosis of hypertrophic cardiomyopathy
Am J Cardiol
(2006) - et al.
Hypertrophic cardiomyopathy in adulthood associated with low cardiovascular mortality with contemporary management strategies
J Am Coll Cardiol
(2015) - et al.
Clinical course of hypertrophic cardiomyopathy with survival to advanced age
J Am Coll Cardiol
(2003) - et al.
2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines
Circulation
(2011)
Cited by (88)
Septal Perforator Artery Doppler Flow in Hypertrophic Cardiomyopathy: Searching for Clinical Applicability
2024, Journal of the American Society of EchocardiographyAge-dependent association of metabolic dyslipidemia with clinical expression of hypertrophic cardiomyopathy
2024, International Journal of CardiologyMyocardial Work Appraisal in Transthyretin Cardiac Amyloidosis and Nonobstructive Hypertrophic Cardiomyopathy
2023, American Journal of CardiologyMultimodality imaging of hypertrophic cardiomyopathy
2023, Progress in Cardiovascular DiseasesUnmet needs and future directions in hypertrophic cardiomyopathy
2023, Progress in Cardiovascular DiseasesThe evolving paradigm and current perception of hypertrophic cardiomyopathy: Implications for management
2023, Progress in Cardiovascular Diseases
See page 1653 for disclosure information.